Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 3, 2006, Pages 842-848

  Cury, Fabio L B ^a   Souhami, Luis ^a,b   Rajan, Raghu ^a   Tanguay, Simon ^a   Gagnon, Bruno ^a   Duclos, Marie ^a   Shenouda, George ^a   Faria, Sergio L ^a   David, Marc ^a   Freeman, Carolyn R ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Androgen ablation; Intermittent hormonal therapy; Prostate cancer; Quality of life; Radiotherapy

Indexed keywords

BIOCHEMISTRY; DRUG DOSAGE; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

ANDROGEN ABLATION; INTERMITTENT HORMONAL THERAPY; PROSTATE CANCER; QUALITY OF LIFE;

HORMONES;

GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HORMONE RESISTANCE; HOT FLUSH; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BUSERELIN; DRUG RESISTANCE, NEOPLASM; HOT FLASHES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; REFERENCE VALUES; TESTOSTERONE;

EID: 31844443482     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.08.034     Document Type: Article

References (33)

1. National Cancer Institute of Canada Canadian Cancer Statistics 2004 Toronto, Canada.
2. W.U. Shipley, J.D. Lu, M.V. Pilepich Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy A secondary analysis of the randomized protocol RTOG 86-10 Int J Radiat Oncol Biol Phys 54 2002 1302 1310
3. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) A phase III randomised trial Lancet 360 2002 103 106
4. G.E. Hanks, T.F. Pajak, A. Porter The Radiation Therapy Oncology Group Protocol 92-02 Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate J Clin Oncol 21 2003 3972 3978
5. C.A. Lawton, K. Winter, K. Murray Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946
6. G.E. Hanks Long-term control of prostate cancer with radiation. Past, present, and future Urol Clin North Am 23 1996 605 616
7. W.U. Shipley, H.D. Thames, H.M. Sandler Radiation therapy for clinically localized prostate cancer A multi-institutional pooled analysis JAMA 281 1999 1598 1604
8. A.V. D'Amico, J.W. Moul, P.R. Carroll Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure J Natl Cancer Inst 96 2004 509 515
9. R.T. Oliver, D. Farrugia, W. Ansell Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients Prostate Cancer Prostatic Dis 3 2000 286 289
10. D. Prapotnich, K. Fizazi, B. Escudier A 10-year clinical experience with intermittent hormonal therapy for prostate cancer Eur Urol 43 2003 233 239
11. M. Pether, S.L. Goldenberg Intermittent androgen suppression BJU Int 93 2004 258 261
12. M.H. Rashid, U.B. Chaudhary Intermittent androgen deprivation therapy for prostate cancer Oncologist 9 2004 295 301
13. A. Hurtado-Coll, S.L. Goldenberg, M.E. Gleave Intermittent androgen suppression in prostate cancer The Canadian experience Urology 60 2002 52 56
14. P.J. Van Cangh, B. Tombal, J.L. Gala Intermittent endocrine treatment World J Urol 18 2000 183 189
15. M.W. Kattan, P.A. Fearn, S. Leibel The definition of biochemical failure in patients treated with definitive radiotherapy Int J Radiat Oncol Biol Phys 48 2000 1469 1474
16. N.K. Aaronson, S. Ahmedzai, B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30 A quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
17. G. Borghede, M. Sullivan Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30 Qual Life Res 5 1996 212 222
18. E.L. Kaplan, P. Meier Nonparametric estimation for incomplete observations J Am Stat Assoc 53 1958 457 481
19. L.H. Klotz, H.W. Herr, M.J. Morse Intermittent endocrine therapy for advanced prostate cancer Cancer 58 1986 2546 2550
20. K. Akakura, N. Bruchovsky, S.L. Goldenberg Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen Cancer 71 1993 2782 2790
21. R.T. Oliver, G. Williams, A.M. Paris Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer Urology 49 1997 79 82
22. C.S. Higano, W. Ellis, K. Russell Intermittent androgen suppression with leuprolide and flutamide for prostate cancer A pilot study Urology 48 1996 800 804
23. A. Horwich, R.A. Huddart, J. Gadd A pilot study of intermittent androgen deprivation in advanced prostate cancer Br J Urol 81 1998 96 99
24. G.D. Grossfeld, E.J. Small, P.R. Carroll Intermittent androgen deprivation for clinically localized prostate cancer Initial experience Urology 51 1998 137 144
25. J.M. Crook, E. Szumacher, S. Malone Intermittent androgen suppression in the management of prostate cancer Urology 53 1999 530 534
26. M. Pether, S.L. Goldenberg, K. Bhagirath Intermittent androgen suppression in prostate cancer An update of the Vancouver experience Can J Urol 10 2003 1809 1814
27. N. Sato, K. Akakura, S. Isaka Intermittent androgen suppression for locally advanced and metastatic prostate cancer Preliminary report of a prospective multicenter study Urology 64 2004 341 345
28. C.W. Gregory, R.T. Johnson Jr., J.L. Mohler Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Res 61 2001 2892 2898
29. A. Hobisch, M. Fiechtl, B. Sandahl-Sorensen Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression Prostate 59 2004 401 408
30. T. Pickles, A. Agranovich, E. Berthelet Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma Cancer 94 2002 362 367
31. R.J. Nejat, H.H. Rashid, E. Bagiella A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy J Urol 164 2000 1891 1894
32. C. Carani, D. Zini, A. Baldini Effects of androgen treatment in impotent men with normal and low levels of free testosterone Arch Sex Behav 19 1990 223 234
33. R. O'Carroll, C. Shapiro, J. Bancroft Androgens, behaviour and nocturnal erection in hypogonadal men The effects of varying the replacement dose Clin Endocrinol (Oxf) 23 1985 527 538